Background: Nitric oxide has a wide variety of homeostatic and pathological effects. Control of the production of nitric oxide by the inducible form of the enzyme resides in the 5' promoter region of the gene. Although control of the murine isoform has been investigated, little is known about the functional aspects of the human analog. Materials and Methods: A 3.9-kb 5' nontranslated region of the human gene was cloned, sequenced, and several reporter constructs prepared. The promoter-reporter constructs were transfected into human or mu-
INTRODUCTION
The free radical nitric oxide (NO) has pleiotropic effects in many mammalian systems, including a central role in controlling blood pressure (1) , as a neurotransmitter (2) , as an effector in retinotectal innervation (3) , and as a microbicidal/tumoricidal factor within some cells of the immune axis (4) . More recent data strongly implicate NO as a mediator of tissue damage in a variety of disease states, including autoimmunity and viral infections (5, 6) , disorders in immune surveillance (7) , as well as septic shock and cytokine-induced hypotension (8, 9) .
Three classes of NO-producing enzymes were initially identified based on their cellular origin or on the mechanism controlling their expression. The distinguishing criteria are the dependence or independence of the enzymes on calcium concentration and the cell type in which the isoform was first identified. The constitutive nitric oxide synthases (cNOS), which include two members first isolated from endothelial cells and neurons, share an expression control mechanism based on intracellular calcium concentration and calmodulin binding (reviewed in Ref. 10) ; the activity is modulated post-transcriptionally. A third isoform, inducible nitric oxide synthase (iNOS) (1 1-13) is found in many cell types. It is distinguished by its induction at the transcriptional level by certain bacterial products and inflammatory cytokines via the promoter response elements in the 5' noncoding region of the gene (reviewed in Ref. 14) . Although iNOS also binds calmodulin, it does so at physiological calcium levels present in the resting cell, and thus is not modulated in response to calcium 227 fluxes, but rather in response to promoter activation following signal transduction (14) .
iNOS is further distinguished from cNOS enzymes in that it appears to be involved primarily as a part of host defense mechanisms. The gramnegative bacterial toxin lipopolysaccharide (LPS) induces murine iNOS expression in several cell types, and iNOS is up-regulated by several cytokines in a species-dependent manner. iNOS is induced in murine rnacrophages by the synergistic action of LPS and interferon--y (IFNy) (14, 15) . The molecular basis of this synergy was recently elucidated by Xie and coworkers (16) , who demonstrated that a 1749-bp segment 5' to the murine iNOS gene contained a series of 22 regulatory elements. However, only two of the elements were required for up-regulation of a reporter construct mimicking the behavior of native iNOS, but the two elements conferred sensitivity to LPS and IFNy in a synergistic manner.
More recently, a molecular clone containing the human iNOS 5' promoter region was obtained (17) and found to be highly homologous to the murine sequence. Functional analysis to determine whether the activation signals effective in inducing expression of mouse iNOS also operate for the human analog were not reported. Intact human iNOS-producing cells have a requirement for at least three concomitant activators for iNOS induction. Certain human cell types, notably macrophages, appear to be completely refractory to iNOS induction, although the murine analogs express high levels of iNOS following cytokine induction.
Because the cloned fragment of the human and mouse iNOS promoters are so similar, we reasoned that perhaps critical promoter response elements may reside 5' to the previously studied region of the reported sequence. We also noted that the frequency of promoter binding sequences in the human iNOS 5' region did not diminish toward the 5' boundary of the reported clone as would be expected if the entire promoter region had been isolated. We therefore undertook the isolation and functional characterization of a significantly longer section of the putative human iNOS promoter region. We report here that an additional 2713-base segment which we have cloned and sequenced contains a high frequency of recognized consensus regulatory elements. Functional studies showed that the critical control elements appear to be clustered within the first 1500-bp region 5' to the transcription start site. Our studies also indicate that although the human and mouse promoter regions appear homologous based on sequence comparisons, the two regions differ significantly in their ability to up-regulate the transcription of reporter constructs in cells of murine or human origin. Finally, our studies showed that activation of the human promoter-reporter occurred with either interleukin 1,3 (IL-13) or tumor necrosis factor a (TNFa) alone, but that IFN-y was absolutely required for the production of NO, indicating that control of NO expression in human cells is controlled at a minimum of two levels.
MATERIALS AND METHODS
Preparation of cDNA Probes Colonies containing full or partial DNA fragments of the human iNOS 5'-flanking sequence were identified by hybridization with a 425-base fragment obtained by polymerase chain reaction (PCR) from human DNA (12) . The fragment was generated by PCR amplification using 5 screened using a 33P-labeled cDNA fragment generated by PCR. Two colonies specifically hybridized with the probe and were picked for further characterization. Based on preliminary experiments, the region of interest lay between an Xbal and an EcoRl site within the clones. The colonies were digested with the enzymes and the products separated on a 1.0% agarose gel. The restriction fragment identified by southern hybridization was directly cloned into a pBluescript vector (Stratagene, San Diego, CA, U.S.A.) and sequenced using an automated DNA sequencer. The murine iNOS pro-moter region was prepared by PCR using a 5' primer, AAAAACGTACACGAGGTGCVGACT (18) , the cNOS inhibitor trifluoperazine (Sigma 100 ,uM) was added to all NO assays so that the detected activity represented only iNOS. Some experiments were also done in the presence of either 100 ,uM methyl L-arginine or the enantiomer D-arginine, which was approximately 10-fold less effective in blocking the enzymatic conversation of arginine to citrulline. The mixture was incubated for 60 min at 37°C. A 1 50-tl aliquot was loaded onto a cation exchange column (AG 50W-Xg; Bio-Rad, Richmond, CA, U.S.A.) and eluted with water. The eluate was collected and the radioactivity quantified by liquid scintillography.
The sequence of the human iNO synthase promoter region reported here was submitted to Genbank, and the accession number is Z4925 1.
RESULTS
We have cloned and completely sequenced a 3923-bp region of the human iNOS gene which includes the transcriptional start site of the iNOS enzyme as well as the first exon of the gene. This clone contains the 425-bp promoter region previously reported by Chartain and coworkers (12 (Fig. 1) ; (ii) in the 5' region distal to that sequenced by Chartain, we found a AAA triplet at -1034 through -1032, which was not reported by Nunokawa (17) .
Analysis of the nucleotide sequence of the 5' noncoding region of the human iNOS gene re- CCATACCCAGCTAATmAtT'TscAATTTTCTGTAGAGATtwTGkCTCActATGTTCCGGT_ CTGArCTGGCTCAGcC ACTCCA -234 6
CTCAGCCTCCCAAATTGCTGaTCA_ ATGACACCGTGCCCAGCCATCTTGTCAC TTTCTARAATGCATTGCTCTTCALTGGCAGATGCTCCAT -2 24*6
AAGCCCAGtCAGGCAT CATC
TCTCCCTGCGTGGTGTGCATCCGACATTAACAAxACTTGCTmtTTCTCTAT -214*6
TATTAATCTGTCTT TTGTTACAGTGTCTTTCCCAACAAAkTAACTTAACATGALTTGIUAGGAAATTATATTTCCTTCCCAGCTGGCTAATTCCAAATGTGT -20o46
CCTCAAr.CCTGGTGCTTGGACSCAAbCCCTGCCACAGGTCAAGAATGCCACACCAAGCAGACGCTGTGTTAGAGGGGCACCTGAGGTGt^ATGTTTGACA -1l94 6 GTAtCATACGATAACTGAATTTCTGcAmAcGGAA^GTCGCmGAGTCTTGACAAGTAGATwmTGGRTCTGAGGAtTTGCCRTGATAGCAAPT -18 46
AGTAGTATCCCCCTCAGAGGCTCTTGGGTwGGGCATTAxATGTGTTAAGACATGTGTTT-GCTGCAGcTA-TAGCCAGAATATGTGRA--AGC------AG -17 54
GCGCATGTGTGCACATGAGTGT-GCAGGTATATGTACGG"AGCtAUACMT-CTCAGCTCTTGTTCCCAGGTrACCCArGCATCTCTCACCAGCCTGGA -1I441I
ACCAGCTACATCAGCA GCAAGPATCAGGTCACCCACAGGCCCTGGCAGTCACACtCATAMSSTAGCTAACtG-TAtCACAA-GCTGWGGIUACTC -84
AAAAA^AAAGCCTTTATGCMAAAAAAACTCTCTGGATGGCAkTGGGGGtAbGV ATACTTCTTGGCTGCCAGTG;TGT'TC. A similar construct was made using the murine iNOS promoter region as described by Xie and coworkers (16) . The reporter constructs were transfected into the murine macrophage cell line RAW 264.7 or the human lung epithelioid cell line A549 which expresses NO following exposure to specific cytokines (18) . As shown in Fig. 2 Luciferase activity was normalized to the activity of the 13-galactosidase transfection control.
GCTTCACTCAGCACAG------------CCCATCCACTATTCTGCCCAAGCTGACTTACTACTAGTGGG-GRAATGCTGGTCAGAC------------GG
We examined the activity of the murine and human reporter plasmids more extensively in A549 cells. Three different lengths of the human promoter were tested to identify the critical regions responsible for biological activity (Fig. 3) . The 425 bp proximal to the transcription start site had minimal to no promoter activity. The 1800-bp clone, which closely matched the murine construct in size and original genomic position, had a significantly greater promoter activity, while the entire 3700-bp promoter region demonstrated less activity. The activity of the murine promoter-reporter construct consistently exceeded that of the human analog by 5-to 7-fold in A549 cells (Fig. 3, inset) . The shown). Additionally, although the 1800-and 3700-bp constructs differed significantly in size, incorporation into PGL vectors resulted in more similar total masses (7500 versus 9300 bp) minimizing the molar differences used in transfection. Because the 1800-bp promoter-reporter construct showed maximal activity in our test system, we used it for a comparison of the relative influence of the cytokines present in the activation mixture with both mouse and human promoter-reporter constructs. With a mixture of IL-1(3, IFN'y, and TNFa, the promoter activation reached a maximum at 8 hr (Fig. 3, inset) and this was consequently used as the standard activation period in all subsequent experiments. A549 cells were transfected with the human or mouse constructs and then exposed to an 8-hr cytokine activation period. The product of the reporter gene was then quantified, and the results are presented in Fig. 4 . The human promoter driving luciferase expression had the greatest activity when cells were treated with IL-1(3 alone, and this maximum was slightly but significantly diminished in the presence of IFNy. TNFa used alone resulted in slight stimulation of the human iNOS promoter, while IFNy alone had no stimulatory activity for the promoterreporter construct in A549 cells. The activity of the mouse promoter increased with addition of IFN,y and TNFa along with IL-i 3, while the activation of the human promoter diminished when TNFa or IFNy was added to IL-13. For the mouse promoter, the greatest stimulation was achieved with the combination of IFNy, TNFa, and IL-1iB. Thus, combined effects of IL-I 3 with other cytokines differed for the human and mouse promoters tested in A549 cells. The specificity of the cytokines stimulating effect was demonstrated by the absence of induced activity when neutralizing antibodies to the respective cytokines were added before cytokine stimulation (data not shown). LPS had no detectable effect on the induction of the promoter as measured by luciferase activity (not shown).
Simultaneous analysis of both luciferase and iNOS activity in A549 cells transfected with the human 1800-bp promoter/reporter construct following stimulation with one or more cytokines revealed differences in the relative stimulation of the two activities (Fig. 5) . Activation of luciferase was evident in A549 cells treated with either IL-i,B alone or, to a lesser extent, TNFa alone, whereas only a small increase above baseline was seen in iNOS activity under either of these conditions. The single addition of IFNy had a marginally suppressive effect on both luciferase and iNOS activities. IL-P1,, the most potent upregulator of reporter gene activity in A549 cells, did not significantly increase the production of NO. However, addition of IFN'y together with IL-13 greatly enhanced the production of NO over that seen with IL-113, while slightly but consistently decreasing the measured luciferase product. When TNFa was added together with IL-113 and IFN'y, an even larger increase in NO production was observed, while the activity of the luciferase reporter was unaffected or suppressed. Nitric oxide production, as determined by the arginine to citrulline conversion assay were confirmed by reverse transcriptase PCR and Northern blot assays detecting iNOS-specific mRNA, and nitrite concentrations in culture supernatants were quantified by the Griess reaction (data not shown).
DISCUSSION
We have isolated, cloned, and sequenced a 3814-bp region of the human iNOS promoter region which contains an additional 2713 bp beyond that previously published (12, 17 To determine the regions of the promoter region necessary for the activation of human iNOS, we constructed three reporter plasmids containing a luciferase reporter gene coupled to 400-, 1800-, or 3800-bp fragments of the cloned human promoter as well as a construct containing a 1500-bp fragment of the mouse iNOS promoter region previously reported (16) . Transfection experiments showed that the 1800-bp promoter-reporter construct was the most active in human A549 cells. The 400-bp promoter construct demonstrated minimal to no activity, perhaps because the region contained the PREs previously found to be important only for LPS induction (16, 19) . We found that LPS had no effect on promoter induction in A549 cells, probably due to the absence of the CD 14 cellular receptor required for endotoxin inducibility (20) . Interestingly, the 3800-bp human promoter/reporter construct was less potent than the 1800-bp fragment. Analysis of the cloned sequence upstream of the 1800-bp fragment failed to identify any known negative regulatory elements, raising the possibility that a novel element of this region may negatively affect transcription of the gene. Alternatively, the presence of oligomeric repeats of AT The murine construct functioned well in both human and mouse cells, and the activity of the construct was consistently greater than that of its human counterpart in all cells tested (A549, GO-G-UVW astrocytoma, HepG2, and RAW cells).
Comparison of the ability of the 1800-bp human promoter construct to drive the transcription of the luciferase gene with the concomitant production of NO from the endogenous human iNOS promoter revealed discordance in the relative stimulation by different cytokines (Fig. 5) . IL-,13 activation alone was sufficient to significantly upregulate transcription of the luciferase reporter gene, but no concomitant increase in NO production was observed. With the addition of IFNy, NO production, but not luciferase activity, was significantly increased. Because addition of IFNy did not induce increased NO production when tested alone, it must complement the stimulatory activity of IL-IO in an indirect manner. TNFa, when added to IL-1iB plus IFNy further increased NO production, but did not increase luciferase activity suggesting that the mechanism of action of TNFa is different from that of IFNy; the latter two cytokines acted in an additive manner for the increased expression of NO, but not for the human iNOS promoter driven reporter construct. We found no evidence of this for the increase in the expression of the reporter luciferase gene (Fig. 5) .
Previous investigators have reported the effects of various cytokines, including IFN-y, on NO inducibility by assaying the increase in iNOS mRNA levels (21, 22) . Levels of mRNA were unaffected by IFN'y, suggesting that its activity in up-regulating NO production is exerted after transcription. Interferons were shown to stabilize niRNAs containing octomer repeats of UUAUUUAU in the 3' untranslated regions of certain cytokine-induced mRNAs (23) , and iNOS mRNA stability is reportedly governed by the same mechanism (21) . The human iNOS gene reported by Chartain et al. (12) contains such repeats in the 3' untranslated region, but the luciferase gene used in the present experiments did not. This suggests one possible mechanism to explain the ability of IL-1, to drive human iNOS promoter luciferase activity, but not to up-regulate the expression of NO. IFNy might either stabilize the iNOS mRNA or selectively prevent the synthesis of a protein critical to the iNOS mRNA destabilization process. Alternatively, other regulatory elements might be within the iNOS gene itself or further downstream. Experiments to test these possibilities are in progress.
The experiments reported here indicate that, although the human and murine iNOS genes share significant sequence and structural homology, differences exist in the control of their respective requirements for activation. The data also suggest that human iNOS expression is influenced by both transcriptional and post-transcriptional events, as expected for a gene with such a broad homeostatic role and pathogenic potential. Further work is needed to understand the full range of mechanism controlling iNOS expression in the human cell types that express iNOS.
